Overview
Alltrna develops universal tRNA medicines to restore disrupted protein production by reading through premature termination codons, targeting thousands of rare and common diseases with shared genetic mutations. The company's AI/ML-powered platform designs, engineers, synthesizes, and delivers chemically modified tRNA oligonucleotides with enhanced potency and activity. Founded in 2018 by Flagship Pioneering, Alltrna pioneers tRNA therapeutics to modulate protein expression and treat genetic disorders.
Frequently asked questions
- What is Alltrna's core technology platform?
- Alltrna's platform uses proprietary AI/ML tools and internal expertise to design, modify, synthesize, and deliver chemically modified tRNA oligonucleotides that read through premature stop codons and restore full-length protein production.
- What diseases does Alltrna target?
- Alltrna targets thousands of rare and common diseases caused by premature termination codons or nonsense mutations, enabling a unified tRNA medicine approach regardless of the specific gene affected.
- What is the development stage of Alltrna's tRNA medicines?
- Alltrna has validated its platform with in vivo demonstrations of tRNA readthrough for common premature stop codons and pioneered chemical synthesis processes for modified tRNAs, with a pipeline focused on Stop Codon Diseases.